- Published at
- by manilatimes.net
mixed
mixed
News for Global Blood Therapeutics, Inc. (GBT)
- Published at
- by livemint.com
mixedmixedPfizer CEO, Under Fire, Will Do ‘Whatever It Takes’ to Grow
Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement from activist investor Starboard Value LP.- Published at
- by gurufocus.com
neutralneutralPfizer (PFE) Shares Rise on Starboard Value's $1 Billion Investment
Pfizer's (PFE) stock saw an uptick after reports emerged that activist investor Starboard Value has invested $1 billion in the pharmaceutical giant. This develo- Published at
- by investing.com
mixedmixedPfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say By Reuters
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say- Published at
- by finance.yahoo.com
mixedmixedShould Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer.- Published at
- by globenewswire.com
positivepositiveGlobal Melatonin Market to Surpass USD 1032.54 million by 2030 Driven by Rise in Insomnia
SkyQuest projects that the global melatonin market will attain a value of USD 1032.54 million by 2030, with a CAGR of 11% during the forecast period...- Published at
- by investing.com
mixedmixedAligos Therapeutics bolsters executive team with new VPs By Investing.com
Aligos Therapeutics bolsters executive team with new VPs- Published at
- by globenewswire.com
neutralneutralSickle Cell Disease Treatment Market Size Projections Exhibit a CAGR of 20%, Likely to Attain a Value of USD 12.38 Billion by 2032
The global sickle cell disease treatment market size is anticipated to grow from USD 2 billion to USD 12.38 billion in 10 years. The market will experience...- Published at
- by forbes.com
positivepositiveHow Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 Billion
Chronicling Dr. Ted Love's CEO journey in biotech and the sale of his sickle cell company Global Blood Therapeutics which Pfizer acquired in August 2022 for $5.4 billion- Published at
- by globenewswire.com
mixedmixedLexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments...- Published at
- by globenewswire.com
mixedmixedHemoglobinopathy Market is Anticipated to reach US$ 1,745.7 Million by 2034: Fact.MR Report
Prominence of Personalized Medicine Approaches as a Notable Trend in the Hemoglobinopathy Market...- Published at
- by globenewswire.com
mixedmixedSickle Cell Disease Treatment Market Worth $4.69 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
The global sickle cell disease treatment market is growing at a CAGR of 19.1% from 2022 to 2030....- Published at
- by globenewswire.com
mixedmixedMalaria and Sickle Cell Disease Treatment Market Worth $29.17 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
The global malaria and sickle cell disease treatment market is growing at a CAGR of 26.5% from 2022 to 2030....- Published at
- by globenewswire.com
neutralneutralSickle Cell Disease Treatment Market Size to Surpass USD 9.84 Billion by 2030, exhibiting a CAGR of 20.1%
As per the report by Fortune Business Insights, the global Sickle Cell Disease Treatment Market size is projected to reach USD 9.84 billion in 2030, at a...- Published at
- by globenewswire.com
mixedmixedSickle Cell Disease Treatment Market Size to Surpass USD 8.75 Billion by 2029, exhibiting a CAGR of 21.4%
As per the report by Fortune Business Insights, the global Sickle Cell Disease Treatment Market size is projected to reach USD 8.75 billion in 2029, at a...- Published at
- by thepost.on.ca
mixedmixedCOVID-19 vaccine winners suffer reversal of fortune
Pharma companies have yet to provide investors with convincing post-pandemic strategies. Read more.- Published at
- by prnewswire.com
mixedmixedSickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ Pharma Companies Rigorously Developing Drugs for the Market Entry
/PRNewswire/ -- DelveInsight's 'Sickle Cell Disease Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and...- Published at
- by investing.com
neutralneutralReata Pharma Appoints Rajiv Patni as EVP and Chief Research & Development Officer By Investing.com
Reata Pharma Appoints Rajiv Patni as EVP and Chief Research & Development Officer- Published at
- by marketscreener.com
mixedmixedReata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
Reata Pharmaceuticals, Inc. , a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv... | June 13, 2023- Published at
- by prnewswire.com
mixedmixedSickle Cell Disease Market to Observe Impressive Growth, Predicts DelveInsight | Key Companies Active in the Domain - Sanofi, Novartis, Vertex, CRISPR, Vifor, Pfizer, GlaxoSmithKline, Alexion, Global
/PRNewswire/ -- DelveInsight's Sickle Cell Disease Market Insights report includes a comprehensive understanding of current treatment practices, sickle cell...